---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-024973"
form_type: "8-K"
ticker: "NNVC"
cik: "0001379006"
company_name: "NANOVIRICIDES, INC."
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:09:46.499529+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NanoViricides defers TheraCour milestone payments until revenue; CEO extends Line of Credit

## Summary
- Amendment to TheraCour license defers future cash milestone payments (Milestones 4-7) until company achieves a Revenue Event; capped at 50% of Recognized Revenue.
- Milestones 1,2,3 already paid: 100k Series A Preferred shares, 50k Series A Preferred shares, and $1.5M via 331,859 shares in lieu of cash.
- CEO Dr. Anil Diwan extended $2M line of credit maturity from Dec 31, 2024 to Dec 31, 2025; no draws to date.
- TheraCour agreed to suspend two-month advance payment requirement until company raises sufficient capital.

## SEC filing metadata
- accession: 0001104659-24-024973
- form_type: 8-K
- ticker: NNVC
- cik: 0001379006
- company_name: NANOVIRICIDES, INC.
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/tm246547d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-024973
- JSON: https://secwatch.observer/filing/0001104659-24-024973.json
- Plain text: https://secwatch.observer/filing/0001104659-24-024973.txt

## Key facts
- Material Agreements
  NANOVIRICIDES, INC. entered into Line of Credit Agreement with Dr. Anil R. Diwan valued at $2,000,000 (effective 2023-11-13).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Dr. Anil R. Diwan
  - Value: $2,000,000
  - Effective: 2023-11-13
  source text: on November 13, 2023, the Company and the Company’s President and CEO, Dr. Anil R. Diwan, entered into a Line of Credit Agreement whereby Dr. Diwan agreed to provide a standby Line of Credit to the Company in the maximum amount of $2,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm
- Material Agreements
  NANOVIRICIDES, INC. entered into License Agreement with TheraCour Pharma, Inc. (effective 2021-09-09).
  - Action: entry
  - Agreement: license
  - Counterparty: TheraCour Pharma, Inc.
  - Effective: 2021-09-09
  source text: NanoViricides, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with TheraCour Pharma, Inc. (“TheraCour”) for an exclusive, worldwide license to the Company for further development with respect to TheraCour’s research and development of services with respect to treatments for coronavirus derived human infections.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm
- Material Agreements
  NANOVIRICIDES, INC. amended Extension Agreement with Dr. Anil R. Diwan valued at $2,000,000 (effective 2024-02-12).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Dr. Anil R. Diwan
  - Value: $2,000,000
  - Effective: 2024-02-12
  source text: On February 12, 2024, the Company, pursuant to Article 2.5 of the Company’s Line of Credit Agreement with Dr. Anil R. Diwan, signed an Extension Agreement which extended the maturity date of the Company’s Line of Credit from December 31, 2024 to December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm
- Material Agreements
  NANOVIRICIDES, INC. amended Amendment with TheraCour Pharma, Inc. (effective 2024-02-13).
  - Action: amendment
  - Agreement: license
  - Counterparty: TheraCour Pharma, Inc.
  - Effective: 2024-02-13
  source text: Amendment to Coronavirus License Agreement As previously disclosed, on September 9, 2021, NanoViricides, Inc. (the “Company”) entered
  evidence_url: https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm
- Material Agreements
  NANOVIRICIDES, INC. amended a license with TheraCour Pharma, Inc. (effective 2024-02-12).
  - Action: amendment
  - Agreement: license
  - Counterparty: TheraCour Pharma, Inc.
  - Effective: 2024-02-12
  source text: nto a License Agreement (the “License Agreement”) with TheraCour Pharma, Inc. (“TheraCour”) for an exclusive, worldwide license to the Company for further development with respect to TheraCour’s research and development of services with respect
  evidence_url: https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.